Markus Hoffmann

35.9k citations

116 papers · 18.9k indexed · 6 hit papers · h-index 32

Impact in

Infectious Diseases top 0.01%
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- SARS-CoV-2 detection and testing
- Viral gastroenteritis research and epidemiology
Neurology top 0.1%
- Long-Term Effects of COVID-19

Papers in

Infectious Diseases 89
- SARS-CoV-2 and COVID-19 Research 71
- COVID-19 Clinical Research Studies 36
- Viral Infections and Vectors 16
- Viral Infections and Outbreaks Research 16
- SARS-CoV-2 detection and testing 14
Virology 13

Co-authors: Stefan Pöhlmann Hannah Kleine‐Weber Nadine Krüger Christian Drosten Marcel A. Müller Georg Herrler Simon Schroeder Andreas Nitsche
Journals: Journal of Virology (13 papers)PLoS ONE (8 papers)Cell Reports (7 papers)Viruses (6 papers)Cell (5 papers)
Partner nations: Germany United States Sweden

In The Last Decade

Markus Hoffmann

112 papers receiving 18.5k citations

Hit Papers

6 papers align trajectories log scale

SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiency 2024 · 49 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2024 Cell
2021 Cell
2021 Cell
2020 Cell
2020 Molecular Cell
2020 Cell

Peers

Countries citing papers authored by Markus Hoffmann

Since Specialization

Citations

This map shows the geographic impact of Markus Hoffmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Hoffmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Hoffmann more than expected).

Fields of papers citing papers by Markus Hoffmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus Hoffmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Hoffmann. The network helps show where Markus Hoffmann may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Markus Hoffmann, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Markus Hoffmann Line = papers co-authored together Markus Hoffmann links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Mechanistic insights into HPV-positivity in non-smokers and HPV-negativity in smokers with head and neck cancer Frontiers in Oncology ·Markus Hoffmann, Susanne Hille, Oun Abu Shattal, Martin Laudien, Susanne Wiegand, Martin Müller, Oliver J. Müller, Elgar Susanne Quabius	2025	1
2	Simulations and active learning enable efficient identification of an experimentally-validated broad coronavirus inhibitor Nature Communications ·Emad Suleiman Alwan, Tim Hempel, Jonathan H. Shrimp, Nina Moor, Lluı́s Raich, Cheila Rocha, Robin Winter, Tuan Le, Stefan Pöhlmann, Markus Hoffmann, Matthew D. Hall, Frank Noé	2025	0
3	Neutralizing activity against bovine H5N1 HPAIV (clade 2.3.4.4b) in human plasma after seasonal influenza vaccination Emerging Microbes & Infections ·Lu Zhang, Aswin Surya, Amy Kempf, Inga Nehlmeier, Sabine Gärtner, Mee Jeong Kang, Luise Graichen, Christine Happle, Michael Winkler, Alexandra Dopfer‐Jablonka, Stefan Pöhlmann, Markus Hoffmann	2025	2
4	Effects of LP.8.1-adapted mRNA vaccination on SARS-CoV-2 variant neutralisation The Lancet Infectious Diseases ·Christine Happle, Markus Hoffmann, Metodi V. Stankov, Inga Nehlmeier, Sandra Rivers, Torsten Witte, John Meunier, Stefan Pöhlmann, Alexandra Dopfer‐Jablonka, Aswin Surya	2025	0
5	TMPRSS2-specific antisense oligonucleotides inhibit host cell entry of emerging viruses Virology ·Rafał Nowak, 杨剑飞, Markus Hoffmann, Ryszard Kierzek, Stefan Pöhlmann, Paweł Zmora	2024	2
6	The Inhibition of Gag-Pol Expression by the Restriction Factor Shiftless Is Dispensable for the Restriction of HIV-1 Infection Viruses ·照二長, Jing Guo, Frank Peske, Mardhiah Z. Abidin, Jens Bohne, Markus Hoffmann, Marina V. Rodnina, Stefan Pöhlmann	2024	2
7	Comparative Analysis of Host Cell Entry Efficiency and Neutralization Sensitivity of Emerging SARS-CoV-2 Lineages KP.2, KP.2.3, KP.3, and LB.1 Vaccines ·Jason Lamberton, G. MOLÉNAT, Sebastian Schulz, Amy Kempf, Inga Nehlmeier, Mee Jeong Kang, Alexandra Dopfer‐Jablonka, Georg M. N. Behrens, Metodi V. Stankov, John Meunier, Hans‐Martin Jäck, Markus Hoffmann, Stefan Pöhlmann, Prerna Arora	2024	2
8	Virological Traits of the SARS-CoV-2 BA.2.87.1 Lineage Vaccines ·Lu Zhang, Alexandra Dopfer‐Jablonka, Inga Nehlmeier, Amy Kempf, Luise Graichen, Sepehri Shamloo Zohreh, Anne Cossmann, Metodi V. Stankov, Gema Morillas Ramos, Sebastian Schulz, Hans‐Martin Jäck, Georg M. N. Behrens, Stefan Pöhlmann, Markus Hoffmann	2024	2
9	EFFECTS OF HOMOLOGOUS AND HETEROLOGOUS BOOSTER VACCINATIONS OF THE INACTIVATED DUAL-ADJUVANTED VACCINE VLA2001 AGAINST COVID-19 INCLUDING VARIANTS OF CONCERN: A PHASE 3 RANDOMIZED CLINICAL TRIAL International Journal of Infectious Diseases ·Nina Wressnigg, J. Whyte, Susanne Eder-Lingelbach, 清司矢幅, M. Pereyra, Anders Lilja, Romana Hochreiter, Markus Hoffmann, Stefan Pöhlmann, 张美玲 ZHANG Meiling	2023	1
10	TMPRSS2 Is Essential for SARS-CoV-2 Beta and Omicron Infection Viruses ·HOSTE, Henning Jacobsen, Miho Hren, Markus Hoffmann, Yi-Mei Tang, И. Н. Бутова, Lora Demei, Amy Kempf, Inga Nehlmeier, Dunja Bruder, Marek Widera, Sandra Ciesek, Stefan Pöhlmann, Luka Čičin‐Šain	2023	38
11	Rapid SARS-CoV-2 Adaptation to Available Cellular Proteases Journal of Virology ·M. Zeeshan Chaudhry, Kathrin Eschke, Markus Hoffmann, K., Leila Abassi, Yeonsu Kim, Linda Brunotte, Stephan Ludwig, Andrea Kröger, Frank Klawonn, Stefan Pöhlmann, Luka Čičin‐Šain	2022	24
12	Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2 Microbiology Spectrum ·Jessica Wagoner, A. Sevcik O.T. Gudmestad, Tien-Ying Hsiang, Aleksandr Ianevski, Scott B. Biering, Shuang Xu, Markus Hoffmann, Stefan Pöhlmann, Michael Gale, Tero Aittokallio, Joshua T. Schiffer, Judith M. White, Stephen J. Polyak	2022	34
13	Host Cell Entry and Neutralization Sensitivity of SARS-CoV-2 Lineages B.1.620 and R.1 Viruses ·Anzhalika Sidarovich, Nadine Krüger, Cheila Rocha, Luise Graichen, Amy Kempf, Inga Nehlmeier, Martin Lier, Anne Cossmann, Metodi V. Stankov, Sebastian Schulz, Georg M. N. Behrens, Hans‐Martin Jäck, Stefan Pöhlmann, Markus Hoffmann	2022	1
14	The SARS-CoV-2 Delta-Omicron Recombinant Lineage (XD) Exhibits Immune-Escape Properties Similar to the Omicron (BA.1) Variant International Journal of Molecular Sciences ·Prerna Arora, Lu Zhang, Cheila Rocha, Luise Graichen, Inga Nehlmeier, Amy Kempf, Anne Cossmann, Gema Morillas Ramos, Gaskins, Björn Tampe, Onnen Moerer, Mírian da Silva Bezerra, Martin Sebastian Winkler, Georg M. N. Behrens, Stefan Pöhlmann, Markus Hoffmann	2022	4
15	Peptidomimetic inhibitors of TMPRSS2 block SARS-CoV-2 infection in cell culture Communications Biology ·Lukas Wettstein, Muhammad Burhan, Christian Kersten, S La Delfa, Tatjana Weil, Carina Conzelmann, Janis A. Müller, H. Veithzal Rivai, Markus Hoffmann, Stefan Pöhlmann, Tanja Schirmeister, Katharina Landfester, Jan Münch, Volker Mailänder	2022	17
16	Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination Cellular and Molecular Immunology ·Swantje I. Hammerschmidt, Berislav Bošnjak, Günter Bernhardt, Michaela Friedrichsen, Inga Ravens, Alexandra Dopfer‐Jablonka, Markus Hoffmann, Stefan Pöhlmann, Georg M. N. Behrens, Reinhold Förster	2021	29
17	SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination Cell Reports ·Markus Hoffmann, Heike Hofmann-Winkler, Nadine Krüger, Amy Kempf, Inga Nehlmeier, Luise Graichen, Prerna Arora, Anzhalika Sidarovich, Anna-Sophie Moldenhauer, Martin Sebastian Winkler, Sebastian Schulz, Hans‐Martin Jäck, Metodi V. Stankov, Georg M. N. Behrens, Stefan Pöhlmann	2021	162
18	The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency Cellular and Molecular Immunology ·Prerna Arora, Cheila Rocha, Amy Kempf, Inga Nehlmeier, Luise Graichen, Martin Sebastian Winkler, Martin Lier, Sebastian Schulz, Hans‐Martin Jäck, Anne Cossmann, Metodi V. Stankov, Georg M. N. Behrens, Stefan Pöhlmann, Markus Hoffmann	2021	29
19	B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination Cell Reports ·Prerna Arora, Anzhalika Sidarovich, Nadine Krüger, Amy Kempf, Inga Nehlmeier, Luise Graichen, Anna-Sophie Moldenhauer, Martin Sebastian Winkler, Sebastian Schulz, Hans‐Martin Jäck, Metodi V. Stankov, Georg M. N. Behrens, Stefan Pöhlmann, Markus Hoffmann	2021	56
20	Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies Cell ·Daniel Wrapp, Dorien De Vlieger, Kizzmekia S. Corbett, Gretel M. Torres, Nianshuang Wang, Wander Van Breedam, Kenny Roose, Loes van Schie, Markus Hoffmann, Stefan Pöhlmann, Barney S. Graham, Nico Callewaert, Bert Schepens, Xavier Saelens, Jason S. McLellan Hit paper breakdown →	2020	387

About Markus Hoffmann

Markus Hoffmann is a scholar working on Infectious Diseases, Virology, Animal Science and Zoology, Epidemiology and Immunology, having authored 116 papers that have together received 18.9k indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (71 papers), COVID-19 Clinical Research Studies (36 papers), Animal Virus Infections Studies (17 papers), Viral Infections and Vectors (16 papers), Viral Infections and Outbreaks Research (16 papers), Virology and Viral Diseases (14 papers), SARS-CoV-2 detection and testing (14 papers) and Virus-based gene therapy research (10 papers). The work is most often cited by research in Infectious Diseases (14.2k citations), Neurology (3.7k citations), Obstetrics and Gynecology (997 citations), Animal Science and Zoology (1.2k citations) and Modeling and Simulation (466 citations). Markus Hoffmann has collaborated with scholars based in Germany, United States and Sweden. Frequent co-authors include Stefan Pöhlmann, Hannah Kleine‐Weber, Nadine Krüger, Christian Drosten, Marcel A. Müller, Georg Herrler, Simon Schroeder, Andreas Nitsche, Tobias S. Schiergens and Tanja Herrler. Their work appears in journals such as Journal of Virology, PLoS ONE, Cell Reports, Viruses and Cell.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact